Wild-type (senile) amyloidosis surgery

Wild-type (senile) amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Wild-type (senile) amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wild-type (senile) amyloidosis surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wild-type (senile) amyloidosis surgery
CDC on Wild-type (senile) amyloidosis surgery
Wild-type (senile) amyloidosis surgery in the news
Blogs on Wild-type (senile) amyloidosis surgery
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Wild-type (senile) amyloidosis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Surgery

• Surgery is not the mainstay of therapy for wild-type (senile) amyloidosis.
• Left ventricular assist devices (LVAD) implantation can be considered but a review of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database is necessary to better evaluate the outcomes of LVAD implantation in these patients.
• Despite the the deteriorating cardiac function of such patients, they are rarely considered for heart transplantation due to their advanced disease presentation, age, and associated comorbidities.